Clinical Trial Update: A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) [Phase 3]

View source ↗

Summary

Phase 3 trial update of setmelanotide for congenital hypothalamic obesity, including related pituitary hormone deficiency conditions, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood-onset Combined Pituitary Hormone Deficiency
• Genetic Form of Multiple Pituitary Hormone Deficiency
• Hypothalamic Obesity
• Optic Nerve Hypoplasia
• Pituitary Stalk Interruption Syndrome
• Septo-optic Dysplasia

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form | Phase 3 | Status: RECRUITING